HOME > TOP STORIES
TOP STORIES
-
BUSINESS With Orix Deal, Reborn Kobayashi Kako Aims to Become Follow-Up to Big 3 Generic Players
February 7, 2020
-
ORGANIZATION RAD-AR Council Accelerating Initiative to Prepare Medication Guides in English toward Tokyo 2020 Olympic and Paralympic Games
February 6, 2020
-
ORGANIZATION Japan Red Cross Set to Push Formularies at All Group Hospitals, Despite Medical Fee Plan Dropped
February 5, 2020
-
BUSINESS Oncolys Hopes for Chugai’s Participation in US Development of Telomelysin: Chief
February 4, 2020
-
BUSINESS Opdivo Sales Drop 4.7% in April-December, but Ono Secures Higher Profits
February 3, 2020
-
BUSINESS Chugai Ups Core EPS CAGR Target to “Around 30%”: 3-Year Biz Plan
January 31, 2020
-
BUSINESS Chugai’s 2019 Earnings Renews Record for Third Year on Hemlibra, Tecentriq
January 31, 2020
-
REGULATORY Takeda’s RCC Drug Cabometyx Now in Line for March Approval; Alecensa, Rozlytrek Opdivo and More
January 30, 2020
-
REGULATORY Japan Ups Responses against Wuhan Coronavirus as First Domestic Transmission Confirmed
January 29, 2020
-
INTERVIEW “Excessive Self-Restraint” of Promotion Activities by Drug Makers Hindering Drugs’ Lifecycle Management: Physician
January 28, 2020
-
REGULATORY Discussions on Off-Year Re-Pricing to Begin in Spring, Focus on Scope of Drugs, Impact on Stakeholders: MHLW Bureau Chief
January 27, 2020
-
REGULATORY ICH’s Guidelines Helped Bring NDMA Contamination Problem to Light: NIHS Officials
January 24, 2020
-
REGULATORY Nasal Steroid Used as “Reference Drug” for Xolair in Special Re-Pricing
January 23, 2020
-
REGULATORY Get Serious about Reviewing Scope of Health Coverage, Says MOF Budget Examiner
January 22, 2020
-
REGULATORY Japan’s Special Re-Pricing Rules to Hit 17 Drugs in April; Potentially Big Slash for Keytruda, Lixiana
January 22, 2020
-
REGULATORY Xolair Faces New Special Re-Pricing Rule; Keytruda, Lixiana Caught by Huge-Seller Price Slash
January 21, 2020
-
BUSINESS Keytruda Snags Best-Seller Title in 2019 Drug Ranking: Encise
January 20, 2020
-
BUSINESS Xolair’s Use Would Be Limited to 1-3% of Pollen Allergy Patients in Japan: Specialist
January 20, 2020
-
REGULATORY MHLW Bureau Chief Says Delay Would Be Inevitable to Revise Drug Distribution Guidelines as Bid-Rigging Probe Continues
January 17, 2020
-
ACADEMIA Impact of Oligonucleotides - 1: Onpattro a Major Advance in FAP Treatment, but Challenges Remain
January 16, 2020
ページ
On paper, things should be looking up for Japan’s pharmaceutical wholesalers. Industry expectations are mounting that the average gap between NHI and market prices will narrow further in FY2026 from the previous year’s record low of 4.8%.A shrinking gap should…
Tariffs have been a defining feature of US trade policy under President Donald Trump’s second administration. Since Trump unveiled his “reciprocal” tariff policy in April 2025, the landscape has shifted repeatedly.In February 2026, the US Supreme Court invalidated tariffs imposed…
